Navigation Links
BMP Sunstone Reiterates Commitment to Quality, Innovation and Long-Term Growth at Meeting with Senior Officials
Date:2/17/2009

PLYMOUTH MEETING, Pa., Feb. 17 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone Corporation (Nasdaq: BJGP) (''BMP Sunstone'' or the ''Company'') announced today that on February 8, 2009, senior executives of Sunstone (Tangshan) Pharmaceutical Co., Ltd., hosted a visit by Zhang Dejiang, the Vice Premier of the State Counsel of the PRC, as well by the head of Hebei provincial government and other senior central and local government officials. During the visit, the Company reaffirmed its dedication to quality, innovation, and long-term growth.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090217/CNTU049 )

Mr. Zhiqiang Han, General Manager and Chairman of the Board of Sunstone, commented, ''As a leading pharmaceutical company in China, with one of the largest granulation facilities in the country, and with a robust product portfolio including Hao Wawa, awarded national brand status in China, we were included in the Vice Premier's recent visit to the region. We are honored and encouraged by this opportunity to represent China's evolving healthcare industry.''

Han continued, ''During the visit, we reiterated our commitment to stringent quality control and innovation, as well as to financial strength. Our dedication to quality and safety is reflected in our ongoing brand leadership, especially in pediatrics and women's health. We have consistently sought to invest in research and development so that we enhance our product offering and have the potential to drive long-term growth. We also remain focused on delivering the best service to our customers as well as enhanced financial performance for our shareholders.''

About BMP Sunstone Corporation

BMP Sunstone Corporation is a specialty pharmaceutical company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China. Currently this portfolio includes eight products under exclusive multi-year licenses for China, primarily focused on women's health and pediatrics. The Company also owns Sunstone Pharmaceutical Co. Ltd., which manufactures leading pediatric and women's health products, including two of China's most recognized brands, "Hao Wawa" and "Confort," sold through approximately 120,000 pharmacies in China. The Company also provides pharmaceutical distribution services through its subsidiaries in Beijing and Shanghai, and through its affiliate, Guangzhou Pharmaceuticals Corp. The Company has its main office in Beijing, with a US office in Plymouth Meeting, PA. For more information, please visit http://www.bmpsunstone.com .

Safe Harbor Statement

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts, including but not limited to statements about the Company's quality control, innovation and financial strength, the long-term prospects of the Company and the Company's intent and ability to enhance its capabilities and realized additional opportunities. These statements are subject to uncertainties and risks including, but not limited to, operating performance, general financial, economic, and political conditions affecting the biotechnology and pharmaceutical industries and the Chinese pharmaceutical market, the ability to timely manufacture and distribute the Company's products and other risks contained in reports filed by the Company with the Securities and Exchange Commission. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

    For more information, please contact:

     Integrated Corporate Relations, Inc.
     Ashley M. Ammon and Christine Duan
     Tel: +1-203-682-8200 (Investor Relations)

'/>"/>
SOURCE BMP Sunstone Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BMP Sunstone Announces Exchange Offer of $10.7 Million of Outstanding Secured Notes
2. BMP Sunstone to Report Third Quarter 2008 Financial Results
3. BMP Sunstone Signs Letter of Intent to Acquire Shengda Pharmaceutical Co.
4. BMP Sunstone Completes Acquisition of Shanghai Rongheng Pharmaceutical Co., Ltd
5. BMP Sunstone Announces Official Launch of Ferriprox in PRC
6. BMP Sunstone Announces Participation in June Investor Conferences
7. BMP Sunstone Reports First Quarter 2008 Financial Results
8. BMP Sunstone Donates RMB 1.2 Million to Earthquake Relief
9. BMP Sunstone Announces Participation in May Investor Conferences
10. BMP Sunstone to Report First Quarter 2008 Financial Results
11. BMP Sunstones Propess(R) Recommended as First Line Treatment By the Chinese Medical Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... , ... April 27, 2017 , ... ... natural deodorant. On the heels of Thinksport’s award-winning sunscreen they’ve used the same ... that actually works! , Countless deodorants flood the aisles that contain harmful chemicals ...
(Date:4/27/2017)... ... April 27, 2017 , ... Goodcents Deli Fresh Subs announced a franchise ... area this year. , The first new location will open at the corner ... at 84th and Northern Lights Drive this fall. And the third location is in ...
(Date:4/26/2017)... MN (PRWEB) , ... April 26, 2017 , ... ... that improve supply management in hospitals, today announced it has completed a round ... Black Granite Capital LLC and its partners. Black Granite Capital is a growth ...
(Date:4/26/2017)... , ... April 26, 2017 , ... ... that describes the adoption of e-prescribing as measured in Part D Medicare data. ... deliver prescriptions to pharmacies, either using e-prescribing, faxes or paper. The PaPR ...
(Date:4/26/2017)... ... , ... Infertility may be a result of an underlying ... women become pregnant upon treating their diagnosis. , To properly diagnose ... We can provide the necessary information to diagnose and treat your problem. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market is ... Low drug registration cost in Latin American countries and continuous ...
Breaking Medicine Technology: